Related Experiment Video
Updated: Dec 1, 2025
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells
Daniel A Pollyea1, Hyun Min Kim2, Brett M Stevens1
1Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Abstract:
Two factors known to contribute to the development of myelodysplastic syndrome (MDS) and other blood cancers are (i) somatically acquired mutations in components of the spliceosome and (ii) increased inflammation. Spliceosome genes, including SF3B1, are mutated at high frequency in MDS and other blood cancers; these mutations are thought to be neomorphic or gain-of-function mutations that drive disease pathogenesis. Likewise, increased inflammation is thought to contribute to MDS pathogenesis; inflammatory cytokines are strongly elevated in these patients, with higher levels correlating with worsened patient outcome. In the current study, we used RNAseq to analyze pre-mRNA splicing and gene expression changes present in blast cells isolated from MDS patients with or without SF3B1 mutations. We determined that SF3B1 mutations lead to enhanced proinflammatory gene expression in these cells. Thus, these studies suggest that SF3B1 mutations could contribute to MDS pathogenesis by enhancing the proinflammatory milieu in these patients.
Insights
Mutations in spliceosome genes like SF3B1 are common in myelodysplastic syndrome (MDS). This study shows these mutations enhance pro-inflammatory gene expression, potentially driving MDS progression.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Myelodysplastic syndrome (MDS) and blood cancers are linked to spliceosome mutations and inflammation.
- SF3B1 mutations are frequent in MDS and may be gain-of-function, driving disease.
- Elevated inflammatory cytokines correlate with poor outcomes in MDS patients.
Purpose of the Study:
- To investigate the impact of SF3B1 mutations on splicing and gene expression in MDS.
- To determine if SF3B1 mutations enhance pro-inflammatory gene expression in MDS blast cells.
Main Methods:
- RNA sequencing (RNAseq) was used to analyze blast cells from MDS patients.
- Gene expression and pre-mRNA splicing patterns were compared between patients with and without SF3B1 mutations.
Main Results:
- SF3B1 mutations were associated with significant changes in gene expression.
- These mutations were found to enhance pro-inflammatory gene expression in MDS blast cells.
Conclusions:
- SF3B1 mutations may contribute to MDS pathogenesis by increasing inflammation.
- Targeting inflammation could be a therapeutic strategy for MDS with SF3B1 mutations.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
10:21Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
Published on: January 5, 2018
